PilaSite data

INSV (Alameda, Calif.) presented initial Phase III results showing that over three months, average intraocular pressure dropped by 20 percent (5.5 mm Hg) in both the 100 patients who received the PilaSite eye drops twice daily and in the 103 patients who used conventional 2 percent pilocarpine eye drops four times a day.

There were significantly fewer drug-related adverse events (p=0.037) and fewer terminations due to adverse events in the PilaSite group than in the pilocarpine group (12 vs. 21 terminations), as detailed at the Association for Research in Vision and Ophthamology meeting in Sarasota, Fla. ...